Immunofoco Presents Phase I/IIa Data of IMC002 at ASCO GI 2026, Highlighting a Durable Complete Response Beyond One Year and a 66.7% ORR in Advanced GC/GEJ
SHANGHAI, Jan. 13, 2026 /PRNewswire/ -- Immunofoco, a clinical-stage biotechnology company advancing innovative CAR-T cell therapies for solid tumors, recently announced clinical data from its Phase I/IIa study of IMC002, a VHH-based anti-CLDN18.2...
2025 ASGCT | Immunofoco's In Vivo CAR-T Technology Platform Debuts with Groundbreaking Innovations
MxV-G is a novel fusogen for lentiviral packaging that achieves higher vector titers and enhanced transduction efficiency. The detargeted MxV-G mutant abolishes native receptor binding while preserving its fusogenic activity. With various TCMs, the...